VCs invest £14m in Storm Therapeutics

New investor Seroba Life Sciences and existing investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participated in the fundraise.

The fresh capital will be used to advance the company's pipeline in pre-clinical development, and accelerate its programmes towards the clinic.

The company has also appointed a vice-president of translational oncology.

Previous funding
Cambridge Innovation invested in a seed round for the company in 2015.

In 2016, Pfizer Ventures, M Ventures, Imperial Innovation and Cambridge Innovation invested £12m in the company.

Taiho invested £4m in Storm in 2018. The company also received a grant of £240,000 in 2018.

Company
Founded in 2015, Storm is a spinout from the University of Cambridge. The company develops drugs for oncology and other diseases through modulating RNA modifying enzymes. The company employs approximately 25 people and is headquartered in Cambridge.

People
Seroba Life Sciences – Bruno Montanari (partner).
Storm Therapeutics – Keith Blundy (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture